AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06588335
Drug: BTLA inhibitor (JS004)
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BTLA inhibitor (JS004):200mg, intravenous infusion , d1, Q3W;
Trial: NCT06588335
Drug: Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab:240mg,intravenous infusion, d1, Q3W;
Trial: NCT06588335
Drug: Paclitaxel, Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paclitaxel, 175mg/m2, intravenous infusion, d1, Q3W; Cisplatin, 75mg/m2, intravenous infusion, d1, Q3W;
Trial: NCT06070766
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The use of ketamine in chronic conditions.
Trial: NCT06585995
Drug: vitamin D (cholecalciferol) supplementation
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This pilot clinical study administered and compared daily and bolus vitamin D dosing regimens to achieve and maintain optimal serum 25(OH)D levels in patients with COVID-19. The daily dose group received constant cholecalciferol supplementation (vitamin D supplementation), aimed at achieving more stable and non-peak 25(OH)D levels. In contrast, the bolus group received a one-month cumulative monthly dose, divided into 4 doses, administered on 4 consecutive days, which could result in rapid increases followed by gradual decreases in 25(OH)D levels. The daily dose of cholecalciferol was calculated using the following formula: Daily dose of cholecalciferol = \[Weight (kg) × desired increase in 25(OH)D (ng/ml) × 2.5\] - 10 .~Bolus dose = (daily dose)(30 days)/4 doses
Trial: NCT06601530
Drug: Tramadol
RxNorm normalized name: Tramadol
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tramadol IV PCA (Patient Controlled Analgesia): Basal infusion 0.2 mg/kg/h, bolus 20 mg, lock time 20 minutes
Trial: NCT05364944
Drug: Debio 4126
RxNorm normalized name: DEBIO-1347
DrugBank: DEBIO-1347 (DB12903)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) injection
Trial: NCT05364944
Drug: Sandostatin LAR
RxNorm normalized name: Sandostatin LAR
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sandostatin LAR will be administered as IM injection as pre-study treatment dose prior to Debio 4126 administration
Trial: NCT05364944
Drug: Somatuline ATG
RxNorm normalized name: Somatuline
DrugBank: Lanreotide (DB06791)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Somatulin ATG will be administered as deep subcutaneous (SC) injection as pre-study treatment dose prior to Debio 4126 administration
Trial: NCT05734196
Drug: INZ-701
RxNorm normalized name: INZ-701
DrugBank: INZ-701 (DB17629)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody.
Trial: NCT02944955
Drug: BLEX 404 Oral Liquid
RxNorm normalized name: Bleximenib
DrugBank: Bleximenib (DB19328)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BLEX 404 Oral Liquid is orally administered twice daily in combination with azacitdine treatment cycles (2 cycles in Part I and 6 cycles in Part II).~Azacitidine treatment: SC or IV injections at 75 mg/m2, QD for 7 days each cycle. 28 days/cycle, and repeat cycles every 4 weeks.
Trial: NCT06131840
Drug: PF-08046050
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given into the vein (IV; intravenous)
Trial: NCT05097287
Drug: Dupilumab
RxNorm normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: solution for injection subcutaneous
Trial: NCT04709601
Drug: Hiprex
RxNorm normalized name: Hiprex
DrugBank: Methenamine (DB06799)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with negative urine culture will be prescribed Hiprex 1 g PO BID x 1 yr and patients with a positive urine culture will be prescribed antibiotics.
Trial: NCT05192889
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given oral (PO).
Trial: NCT05192889
Drug: Navitoclax
RxNorm normalized name: navitoclax
DrugBank: Navitoclax (DB12340)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given oral (PO).
Trial: NCT05192889
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally (PO) or intravenously (IV).
Trial: NCT05192889
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given intravenously (IV).
Trial: NCT05192889
Drug: Calaspargase Pegol
RxNorm normalized name: Calaspargase pegol
DrugBank: Calaspargase pegol (DB14730)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given intravenously (IV).
Trial: NCT05192889
Drug: Dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given oral (PO).
Trial: NCT05192889
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given intravenously (IV) or Intrathecal (IT).
Trial: NCT05192889
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given intravenously (IV).
Trial: NCT05192889
Drug: Pegaspargase
RxNorm normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: May be used in place of Calaspargase Pegol where available. Given intravenously (IV) or intramuscularly (IM).
Trial: NCT05192889
Drug: Erwinia asparaginase
RxNorm normalized name: Erwinia asparaginase
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To be used in case of hypersensitivity or intolerance to Calaspargase Pegol or Pegaspargase. Given intravenously (IV) or intramuscularly (IM).
Trial: NCT04721223
Drug: JAB-3068
RxNorm normalized name: JAB-3068
DrugBank: JAB-3068 (DB17131)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JAB-3068 administrated orally as a tablet.
Trial: NCT04721223
Drug: PD1 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: JS001 administrated as an intravenous(IV) infusion.
Trial: NCT00270010
Drug: epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05183178
Drug: Prasugrel 10 mg p.o
DrugBank: Prasugrel (DB06209)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Prasugrel 10 mg once daily p.o. Patient \>75 years of age or \<60 kg will receive 5 mg prasugrel OD.
Trial: NCT05183178
Drug: Ticagrelor 90 mg
RxNorm normalized name: ticagrelor 90 MG
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor 90 mg twice daily p.o.
Trial: NCT05177510
Drug: Mifepristone
RxNorm normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Progestin Antagonist
Trial: NCT06018766
Drug: LAM-001
RxNorm normalized name: lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LAM-001 administered via dry powder inhaler
Trial: NCT00001116
Drug: Tumor Necrosis Factor soluble receptor-immunoadhesin complex
RxNorm normalized name: Tumor necrosis factor, soluble form, nonglycosylated
DrugBank: Tasonermin (DB11626)
FDA approved: no
EMA approved: yes
PMDA approved: no
Trial: NCT04473989
Drug: recombinant teriparatide for injection
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: weekly subcutaneous administration of 40 ug
Trial: NCT04621981
Drug: Sodium Bicarbonate Ringer's Solution
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This group was treated with Sodium Bicarbonate Ringer's Solution.
Trial: NCT05384249
Drug: Izokibep
RxNorm normalized name: Izokibep
DrugBank: Izokibep (DB19081)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biologic: IL-17A inhibitor~Form: Solution for injection~Route of administration: Subcutaneous (SC)
Trial: NCT05691010
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients enrolled in this trial will receive chemotherapy with carboplatin IV AUC 5 at the discretion of the treating investigator plus paclitaxel 175 mg/m2 every 21 days for 6 cycles
Trial: NCT05691010
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients enrolled in this trial will receive chemotherapy with carboplatin IV AUC 5 at the discretion of the treating investigator plus paclitaxel 175 mg/m2 every 21 days for 6 cycles
Trial: NCT06049589
Drug: Chlorhexidine mouthwash
RxNorm normalized name: chlorhexidine Mouthwash
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine rinsing
Trial: NCT06681090
Drug: 0.1% topical triamcinolone Acetonide preparation Kenacourt-A Orabase
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients were administered topical corticosteroids in the form of a 0.1% triamcinolone acetonide preparation (Kenacort TM 0.1% Abbott). The medication was to be used 3 times every day for 4 weeks or until the lesion has healed, whichever occurs first. After applying the gel, the patients were instructed not to consume any fluids or food for at least 1 hour. In addition, a topical antifungal treatment consisting of Miconazole oral gel at a concentration of 2% should be applied once a day for 4 weeks
Trial: NCT05844592
Drug: INV-101
RxNorm normalized name: INV-REMDESIVIR
DrugBank: Remdesivir (DB14761)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: subjects will be randomized 3:1 ratio
Trial: NCT05021328
Drug: Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab 240mg, ivgtt, d1, q3w.
Trial: NCT05021328
Drug: Anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib 12 mg/d, d1-14, q3w.
Trial: NCT06502145
Drug: Azacitidine Level -1
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous (IV) or subcutaneous (SC) 75 mg / m\^2 days 1-7 X 28 days.
Trial: NCT06502145
Drug: Azacitidine Level 0
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous (IV) or subcutaneous (SC) 75 mg / m\^2 days 1-7 X 28 days.
Trial: NCT06502145
Drug: Azacitidine Level 1
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous (IV) or subcutaneous (SC) 75 mg / m\^2 days 1-7 X 28 days.
Trial: NCT06502145
Drug: Iadademstat Level -1
RxNorm normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 µg by mouth (PO) 5 days on, 2 days off for 2 weeks every 28 days.
Trial: NCT06502145
Drug: Iadademstat Level 0
RxNorm normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 µg PO 5 days on, 2 days off for 3 weeks every 28 days.
Trial: NCT06502145
Drug: Iadademstat Level 1
RxNorm normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 µg PO 5 days on, 2 days off for 3 weeks every 28 days.
Trial: NCT04908579
Drug: bupivacaine(intraperitoneally) and ketamine (intraperitoneally)
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1. 40 ml volume of bupivacaine 0.25% + ketamine 0.5 mg/kg distributed as 30 ml intraperitoneally and 10 ml as port site infiltration~2. 10 ml normal saline 0.9% will be given intravenous.
Trial: NCT04908579
Drug: bupivacaine(intraperitoneally) and ketamine (intravenously)
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1. 40 ml volume of bupivacaine 0.25% only distributed as 30 ml intraperitoneally and 10 ml as port site infiltration~2. 10 ml volume of ketamine 0.5 mg/kg intravenously will be given after delivering the gastric sleeve and before start closure of port sites.
Trial: NCT04908579
Drug: bupivacaine(intraperitoneally)
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1. 40 ml volume of bupivacaine 0.25% only distributed as 30 ml intraperitoneally and 10 ml as port site infiltration~2. 10 ml normal saline 0.9% will be given intravenous.
Trial: NCT05666518
Drug: Vericiguat (Verquvo, BAY1021189)
RxNorm normalized name: Vericiguat
DrugBank: Vericiguat (DB15456)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dosage at the discretion of the treating physician, based on the recommendations written in the product information.
Trial: NCT06417775
Drug: Ubrogepant
RxNorm normalized name: Ubrogepant
DrugBank: Ubrogepant (DB15328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Tablets
Trial: NCT06417775
Drug: Placebo for Ubrogepant
RxNorm normalized name: Ubrogepant
DrugBank: Ubrogepant (DB15328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Tablets
Trial: NCT05238675
Drug: BI 1291583
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1291583
Trial: NCT00000970
Drug: Foscarnet sodium
RxNorm normalized name: Foscarnet Sodium
DrugBank: Foscarnet (DB00529)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00000970
Drug: Ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05473442
Drug: EQU-001
RxNorm normalized name: Eque-cel
DrugBank: Equecabtagene autoleucel (DB19016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg pills of EQU-001
Trial: NCT06370065
Drug: HAIC+Serplulimab（HLX10）+ Bevacizumab Biosimilar（HLX04）
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PD-1 inhibitor
Trial: NCT05005403
Drug: ABBV-514
RxNorm normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) Infusion
Trial: NCT05005403
Drug: Budigalimab
RxNorm normalized name: Budigalimab
DrugBank: Budigalimab (DB16668)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Infusion
Trial: NCT00034606
Drug: Pemetrexed (Alimta) in combination with gemcitabine (Gemzar)
RxNorm normalized name: pemetrexed Injection [Alimta]
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05196815
Drug: Dobutamine
RxNorm normalized name: Dobutamine
DrugBank: Dobutamine (DB00841)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be given a low dose infusion of dobutamine, to make the heart pump quicker and more vigorously.. This will last for approximately 5 minutes
Trial: NCT06789783
Drug: Lithium Carbonate Capsule
RxNorm normalized name: Lithium Carbonate Capsules
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10mg/Kg twice a day, 150mg or 300mg Lithium Carbonate
Trial: NCT05342376
Drug: Dexmedetomidine Hydrochloride
RxNorm normalized name: Dexmedetomidine Hydrochloride
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The parturients will receive 10 micro-gram Dexmedetomidine diluted in 02 ml normal saline to be administered intravenously over 10 minutes after umbilical cord is clamped..
Trial: NCT05319015
Drug: Neoadjuvant Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200 mg IV every 3 weeks for 4 doses prior to surgery
Trial: NCT06502158
Drug: Mifepristone
RxNorm normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 milligrams (mg)
Trial: NCT06502158
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 600 micrograms (ug)
Trial: NCT05795478
Drug: Oxycodone and Pregabalin
RxNorm normalized name: oxycodone and ibuprofen
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oxycodone: 150mg PCIA during 3 days postoperatively Pregabalin: 150mg preoperatvely, 75mg BID for POD1\~7,75mg QD for POD8\~14
Trial: NCT06172205
Drug: intravenous FOLFOX7 plus Camrelizumab and apatinib
RxNorm normalized name: acetaminophen
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leucovorin 200mg/m2 administered IV on Days 1 of a 21 day cycle Oxaliplatin 85 mg/m2 IV on Days 1 of a 21 day cycle Fluorouracil 5-FU continuous infusion: 400mg/m2 on D1 and then 2400mg/m2 for 46h of each 21 day cycle.~Camrelizumab 200mg infusion on D1 for every 21 days Apatinib 250mg，po，qd for every 21 days
Trial: NCT06172205
Drug: HAIC-FOLFOX plus Camrelizumab and apatinib
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-h infusion of oxaliplatin at 85 mg/m2 ,a 2-3-h administration of leucovorin at 400 mg/m2 , and a 46-h delivery of fluorouracil at 2500 mg/m2.~camrelizumab (200 mg intravenously, commencing in 7 days after the first HAIC cycle and repeated every 21 days) and apatinib (250 mg daily, taken orally, beginning in 7 days after the initial HAIC cycle) Camrelizumab 200mg infusion on D1 for every 21 days Apatinib 250mg，po，qd for every 21 days
Trial: NCT05795478
Drug: Oxycodone and placebo capsules
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxycodone: 150mg PCIA for 3 days postoperatively placebo capsules: same numbers as pregabalin at each time point
Trial: NCT06761313
Drug: Bimatoprost .03% sterile ophthalmic solution
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Individuals will be randomly divided em two groups,Group I is going to be treated with Triplenex (1 drop twice a day) and Grupo II with Brimonidine Tartarate 0.2%(1 drop twice a day), Timolol Maleate 0.5% (1 drop twice a day) and Bimatoprost 0.3% (1 drop at night). At the first visit a complete ophthalmolgical exam which includes ocular surface items (conjunctival hiperemia, keratitis and tear film break up time). Questionnaires are performed (Ocular Surface Disease Index, Glaucoma Treatment Compliance Assessment Tool and National Eye Institute Visual Function Questionnaire) to assess information about ocular surface adverse effects, quality of life and treatment adherence. Glaucoma exams as retinography, perimetry, optic nerve OCT (optical coherence tomography), central corneal thickness are performed on all patients to evaluate disease's control. This procedure will be repeated at all visits: baseline and within 4, 8, 12 weeks.
Trial: NCT05005260
Drug: Bupivacaine HCl
RxNorm normalized name: bupivacaine HCl
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects randomized to the continuous interscalene nerve block group will receive a loading dose of 15-20 mL bupivacaine HCl 0.5% followed by a continuous catheter infusion of bupivacaine 0.2% at 8 mL per hour for 72 hours.
Trial: NCT05005260
Drug: Liposomal bupivacaine + Bupivacaine Hcl 0.5% Inj
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive a one-time interscalene nerve block injection of 5 mL of bupivacaine 0.5% (25 mg) admixed with 10 mL of liposomal bupivacaine (133 mg).
Trial: NCT05896683
Drug: Lazertinib
RxNorm normalized name: Lazertinib
DrugBank: Lazertinib (DB16216)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lazertinib will be administered orally.
Trial: NCT05795478
Drug: Pregabalin and NS
RxNorm normalized name: NS-2359
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin: 150mg preoperatively, 75mg BID for POD1\~7,75mg QD for POD8\~14 NS: Equal volume NS for 3 days postoperatively
Trial: NCT05795478
Drug: placebo capsules and NS
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsules: same numbers as pregabalin at each time point NS: Equal volume NS for 3 days postoperatively
Trial: NCT04839562
Drug: Solriamfetol 75 MG
RxNorm normalized name: solriamfetol 75 MG
DrugBank: Solriamfetol (DB14754)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Daily oral consumption
Trial: NCT04839562
Drug: Solriamfetol 150 MG
RxNorm normalized name: solriamfetol 150 MG
DrugBank: Solriamfetol (DB14754)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Daily oral consumption
Trial: NCT06010303
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab will be administered at a standard dose intravenously.
Trial: NCT05263895
Drug: PF-07321332/ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PF-07321332 ritonavir will be administered as single dose orally
Trial: NCT05263895
Drug: PF-07321332/ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PF-07321332 ritonavir will be administered as single oral dose orally.
Trial: NCT06354556
Drug: HRS-1893 tablet
RxNorm normalized name: HRS-1167
DrugBank: HRS-1167 (DB18703)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRS-1893 tablet single dose
Trial: NCT06784479
Drug: Remimazolam and Propofol
RxNorm normalized name: remimazolam
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Application of Remimazolam and Propofol to induce sleep
Trial: NCT06784479
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Application of Propofol to induce sleep
Trial: NCT06354556
Drug: Verapamil tablet
RxNorm normalized name: verapamil Oral Tablet
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Verapamil tablet 80 mg tid
Trial: NCT05263895
Drug: PF-07321332
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-07321332 will be administered as single oral dose orally.